New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - nifedipine 60mg;  ;   - modified release tablet - 60 mg - active: nifedipine 60mg     excipient: carbomer 934p colloidal silicon dioxide hypromellose   iron oxide red lactose monohydrate macrogol 4000 magnesium stearate   methacrylic acid copolymer povidone purified talc   titanium dioxide - treatment of mild to moderate hypertension.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - fexofenadine hydrochloride 120mg;   - tablet - 120 mg - active: fexofenadine hydrochloride 120mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry povidone purified talc purified water sodium laurilsulfate

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - fexofenadine hydrochloride 180mg;   - tablet - 180 mg - active: fexofenadine hydrochloride 180mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opacode povidone purified talc purified water sodium laurilsulfate

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - doxorubicin hydrochloride 2 mg/ml - concentrate for infusion - 2 mg/ml - active: doxorubicin hydrochloride 2 mg/ml excipient: hydrochloric acid sodium chloride water for injection - doxorubicin has produced significant therapeutic responses in a number of solid tumours and haematologic malignancies, and is commonly used in the treatment of the following tumours: · carcinoma of the breast · carcinoma of the lung · carcinoma of the ovary · transitional bladder cell cancer · neuroblastoma · wilm's tumour · soft tissue sarcomas · osteosarcoma · acute lymphocytic-lymphoblastic leukaemia · acute myelogenous leukaemia · non-hodgkin's lymphoma · hodgkin's disease doxorubicin has also shown antitumour activity in the following adult and paediatric malignancies: · carcinoma of the thyroid · carcinoma of the endometrium · carcinoma of the head and neck · carcinoma of the stomach · primary heptacellular carcinoma · non-seminomatous carcinoma of the testis · carcinoma of the prostate · ewing's sarcoma · rhabdomyosarcoma · multiple myeloma · chronic leukaemias

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - sertraline hydrochloride 111.9mg equivalent to 100 mg sertraline;   - film coated tablet - 100 mg - active: sertraline hydrochloride 111.9mg equivalent to 100 mg sertraline   excipient: calcium hydrogen phosphate hyprolose hypromellose macrogol 400 magnesium stearate microcrystalline cellulose polysorbate 80 sodium starch glycolate titanium dioxide - sertraline actavis is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - sertraline hydrochloride 55.95mg equivalent to 50 mg sertraline;   - film coated tablet - 50 mg - active: sertraline hydrochloride 55.95mg equivalent to 50 mg sertraline   excipient: calcium hydrogen phosphate hyprolose hypromellose macrogol 400 magnesium stearate microcrystalline cellulose polysorbate 80 sodium starch glycolate titanium dioxide - sertraline actavis is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - sumatriptan succinate 70mg equivalent to 50 mg sumatriptan - tablet - 50 mg - active: sumatriptan succinate 70mg equivalent to 50 mg sumatriptan excipient: croscarmellose sodium   lactose magnesium stearate   microcrystalline cellulose   purified water - mygran is indicated for acute relief of migraine attacks, with or without aura. it relieves migraine headache and the associated symptoms of nausea and sensitivity to light and sound. mygran should only be used where there is a clear diagnosis of migraine.

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - enalapril maleate 10mg - tablet - 10 mg - active: enalapril maleate 10mg excipient: iron oxide red iron oxide yellow lactose monohydrate magnesium stearate maize starch pregelatinised maize starch sodium bicarbonate

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - enalapril maleate 20mg - tablet - 20 mg - active: enalapril maleate 20mg excipient: iron oxide red lactose monohydrate magnesium stearate maize starch pregelatinised maize starch sodium bicarbonate

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - enalapril maleate 5 mg - tablet - 5 mg